New Data Shows Promise Involving Lenacapavir for the Treatment of HIV

A study published in the journal Nature on July 1 suggests that there may be a new way to target an HIV protein called capsid, which was almost unmanageable in patients until now. Researchers from Gilead Sciences have developed a new drug called lenacapavir, which targets capsid in the body and weakens the HIV virus’ outer coating. In short, it becomes more difficult for the virus to infect the body’s cells and protect itself from the body’s natural defenses.